Drug intelligence / Profile preview

MED201

Development stage: Preclinical
Lead developer: Medley Therapeutics

Overview

MED201 is an investigational therapeutic candidate being developed by Medley Therapeutics for the treatment of fibrotic diseases, primarily idiopathic pulmonary fibrosis (IPF). Currently in the preclinical and IND-enabling stages, MED201 is part of a pipeline focused on regenerative medicine and the modulation of the Hippo pathway (YAP/TAZ) to address chronic organ failure. In addition to IPF, the program is being evaluated for potential use in renal disease. The specific modality (e.g., small molecule, RNA therapy) and the exact molecular target of MED201 have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on MED201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MED201.

Explore the full profile